IS6159A - Fjölgervingar af kristölluðu asabísýkló (2,2,2) oktan-3-amín sítrati og lyfjasamsetningar - Google Patents

Fjölgervingar af kristölluðu asabísýkló (2,2,2) oktan-3-amín sítrati og lyfjasamsetningar

Info

Publication number
IS6159A
IS6159A IS6159A IS6159A IS6159A IS 6159 A IS6159 A IS 6159A IS 6159 A IS6159 A IS 6159A IS 6159 A IS6159 A IS 6159A IS 6159 A IS6159 A IS 6159A
Authority
IS
Iceland
Prior art keywords
octane
pharmaceutical formulations
synthetic crystalline
amine citrate
azabicyclo
Prior art date
Application number
IS6159A
Other languages
English (en)
Inventor
James Castaldi Michael
Joseph Quallich George
Theophilus Wint Lewin
Original Assignee
Pfizer Product Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2000/000665 external-priority patent/WO2000073304A1/en
Application filed by Pfizer Product Inc. filed Critical Pfizer Product Inc.
Publication of IS6159A publication Critical patent/IS6159A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS6159A 1999-06-30 2001-11-13 Fjölgervingar af kristölluðu asabísýkló (2,2,2) oktan-3-amín sítrati og lyfjasamsetningar IS6159A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14168199P 1999-06-30 1999-06-30
PCT/IB2000/000665 WO2000073304A1 (en) 1999-06-01 2000-05-18 Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IS6159A true IS6159A (is) 2001-11-13

Family

ID=22496734

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6159A IS6159A (is) 1999-06-30 2001-11-13 Fjölgervingar af kristölluðu asabísýkló (2,2,2) oktan-3-amín sítrati og lyfjasamsetningar

Country Status (42)

Country Link
US (3) US6465437B1 (is)
EP (1) EP1189913B1 (is)
JP (1) JP2003503506A (is)
KR (1) KR100442508B1 (is)
CN (2) CN101220067A (is)
AP (1) AP2001002370A0 (is)
AR (1) AR035551A1 (is)
AT (1) ATE286906T1 (is)
AU (1) AU772277B2 (is)
BG (1) BG65587B1 (is)
BR (1) BR0012091A (is)
CA (1) CA2376748C (is)
CO (1) CO5190679A1 (is)
CZ (1) CZ20014571A3 (is)
DE (1) DE60017399T2 (is)
EA (1) EA004235B1 (is)
EC (1) ECSP003555A (is)
EE (1) EE05068B1 (is)
ES (1) ES2233380T3 (is)
GT (2) GT200000105A (is)
HN (1) HN2000000090A (is)
HR (1) HRP20010919B1 (is)
HU (1) HUP0201693A3 (is)
IL (1) IL146408A0 (is)
IS (1) IS6159A (is)
MA (1) MA26745A1 (is)
MX (1) MXPA02000058A (is)
MY (1) MY133360A (is)
NO (1) NO20016221L (is)
OA (1) OA11965A (is)
PA (1) PA8496901A1 (is)
PE (1) PE20010287A1 (is)
PL (1) PL201891B1 (is)
PT (1) PT1189913E (is)
SK (1) SK286243B6 (is)
TN (1) TNSN00143A1 (is)
TR (1) TR200103834T2 (is)
UA (1) UA71013C2 (is)
UY (1) UY26221A1 (is)
WO (1) WO2001002414A1 (is)
YU (1) YU88701A (is)
ZA (1) ZA200110453B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) * 2002-02-12 2004-09-14 Seiko Epson Corporation Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN110885351A (zh) * 2019-12-17 2020-03-17 海门慧聚药业有限公司 泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
JP3897983B2 (ja) * 1999-05-18 2007-03-28 ファイザー・プロダクツ・インク マクロライド系抗生物質の新規結晶
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Also Published As

Publication number Publication date
UY26221A1 (es) 2001-01-31
PA8496901A1 (es) 2002-08-26
EE200100699A (et) 2003-02-17
KR100442508B1 (ko) 2004-07-30
HRP20010919B1 (en) 2005-06-30
PL201891B1 (pl) 2009-05-29
ES2233380T3 (es) 2005-06-16
IL146408A0 (en) 2002-07-25
ZA200110453B (en) 2003-03-04
HUP0201693A2 (en) 2002-10-28
AP2001002370A0 (en) 2001-12-31
ECSP003555A (es) 2002-01-25
BG106123A (en) 2002-05-31
CZ20014571A3 (cs) 2002-04-17
JP2003503506A (ja) 2003-01-28
ATE286906T1 (de) 2005-01-15
EP1189913A1 (en) 2002-03-27
WO2001002414A1 (en) 2001-01-11
AR035551A1 (es) 2004-06-16
NO20016221D0 (no) 2001-12-19
US6861412B2 (en) 2005-03-01
US6465437B1 (en) 2002-10-15
EE05068B1 (et) 2008-08-15
HN2000000090A (es) 2001-04-20
SK18922001A3 (sk) 2002-04-04
GT200000105A (es) 2001-12-20
US20040209826A1 (en) 2004-10-21
YU88701A (sh) 2004-09-03
CA2376748C (en) 2006-03-14
BG65587B1 (bg) 2009-01-30
EA200101178A1 (ru) 2002-06-27
PE20010287A1 (es) 2001-03-05
DE60017399T2 (de) 2006-03-30
AU4943900A (en) 2001-01-22
OA11965A (en) 2006-04-12
EA004235B1 (ru) 2004-02-26
MA26745A1 (fr) 2004-12-20
TNSN00143A1 (fr) 2005-11-10
GT200000105AA (es) 2001-12-20
SK286243B6 (sk) 2008-06-06
CO5190679A1 (es) 2002-08-29
EP1189913B1 (en) 2005-01-12
CN1358188A (zh) 2002-07-10
UA71013C2 (uk) 2004-11-15
CA2376748A1 (en) 2001-01-11
DE60017399D1 (de) 2005-02-17
MY133360A (en) 2007-11-30
AU772277B2 (en) 2004-04-22
PL352900A1 (en) 2003-09-22
TR200103834T2 (tr) 2002-05-21
NO20016221L (no) 2001-12-19
KR20020016875A (ko) 2002-03-06
US20030092642A1 (en) 2003-05-15
PT1189913E (pt) 2005-04-29
MXPA02000058A (es) 2002-07-02
US7297682B2 (en) 2007-11-20
CN101220067A (zh) 2008-07-16
HRP20010919A2 (en) 2003-02-28
BR0012091A (pt) 2002-04-02
HUP0201693A3 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
NO992339L (no) Farmasöytiske formuleringer
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
PT1139739E (pt) Formulacoes agroquimicas
DK1168916T3 (da) Landbrugskemikalieformuleringer
ATE209899T1 (de) Feste, schnellzerfallende cetirizin- formulierungen
DK1237408T3 (da) Hæld-på-formuleringer
NO20015670L (no) Forbedrede farmasöytiske formuleringer
IS6398A (is) Lyfjablöndur
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
IL129270A0 (en) Class "d" amplifier
ATE309838T1 (de) Pharmazeutisches implantat
CY2007011I1 (el) Πολυμορφες ενος κρυσταλλικου κιτρικου αλατος αζαδικυκλο (2,2,2) οκταν -3- αμινης και φαρμακευτικες συνθεσεις τους
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
IS6159A (is) Fjölgervingar af kristölluðu asabísýkló (2,2,2) oktan-3-amín sítrati og lyfjasamsetningar
DK1216032T3 (da) Orale formuleringer med kontrolleret frigivelse
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
ES1044994Y (es) Casita infantil perfeccionada.
ES1042703Y (es) "cuadro perfeccionado".
ES1042694Y (es) "expositor perfeccionado".
ES1042364Y (es) "pañal perfeccionado".
ES1042949Y (es) Buzon perfeccionado
ES1045283Y (es) Antichichonera infantil perfeccionada
ES1044751Y (es) Chupete perfeccionado.